1. Home
  2. PETS vs XBIT Comparison

PETS vs XBIT Comparison

Compare PETS & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

HOLD

Current Price

$2.13

Market Cap

61.6M

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.45

Market Cap

73.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETS
XBIT
Founded
1996
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Pharmaceuticals and Biotechnology
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6M
73.2M
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
PETS
XBIT
Price
$2.13
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.4K
21.4K
Earning Date
06-09-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
18.92
N/A
EPS
N/A
N/A
Revenue
$273,800,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$2.09
52 Week High
$4.32
$3.61

Technical Indicators

Market Signals
Indicator
PETS
XBIT
Relative Strength Index (RSI) 34.63 48.50
Support Level N/A $2.15
Resistance Level $2.44 $2.49
Average True Range (ATR) 0.08 0.06
MACD -0.01 -0.01
Stochastic Oscillator 6.21 43.48

Price Performance

Historical Comparison
PETS
XBIT

About PETS PetMed Express Inc.

PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: